Logo for Karyopharm Main Menu Investor Center Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. In June 2020, XPOVIO was approved by the FDA as a treatment for patients with relapsed or refractory diffuse large B-cell lymphoma, and in December 2020 XPOVIO in combination with bortezomib and dexamethasone, was approved for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. In 2021, both the European Commission and UK Medicines & Healthcare Products Regulatory Agency (MHRA) granted conditional marketing authorization for NEXPOVIO® (selinexor) in combination with dexamethasone for the treatment of adult patients with relapsed and or refractory multiple myeloma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. LEARN MORE Recent Filings Annual Report Quarterly Results Proxy Statement Press Releases Nov 11, 2021 Karyopharm to Participate at Jefferies London Healthcare Conference Share now: Nov 4, 2021 Karyopharm Announces New Interim Phase 2 Selinexor Data in Myelofibrosis Selected for Oral Presentation at the American Society of Hematology 2021 Annual Meeting and Exposition Share now: Nov 3, 2021 Karyopharm Reports Strong Third Quarter 2021 Financial Results and Provides Business Highlights Share now: ALL RELEASES Our Corporate Presentation KARYOPHARM CORPORATE PRESENTATION NOV 2021 Events Karyopharm Therapeutics Virtual Investor Day Wednesday, December 8, 2021 10:00am EST Add to Calendar Set Email Reminder ALL EVENTS STOCK INFORMATION NASDAQKPTI $7.11 Last Price -$0.59 (-7.66%) Change 565.0K Volume $537.1M Market Cap Currency in USD. Quote data delayed by at least 15 minutes. Never Miss an Investor Alert Social Channels © Karyopharm, 2020. All Rights Reserved. Terms of Use Privacy Policy Site Map